Pharma cos to lose pandemic-induced pricing power in Q2 as economies reopen: Report

The pharma companies cumulatively saw their pre-tax margins rising by 306 basis points (bps) on an annualised basis and 551 bps sequentially in the first quarter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2CT0DsG
via IFTTT